tbuckley/cabot-search huggingface dataset:
Soldiers injured in Iraq War were let down by lack of dedicated health facilities, Chilcot report finds
Authors: Nigel Hawkes
Journal: BMJ (2016)

The Iraq War was the first major military operation by Britain after the closure of military hospitals, and it showed up failings in the system devised to replace them, the Chilcot inquiry has found.1

Injured soldiers repatriated from Iraq were treated alongside NHS patients at Selly Oak Hospital in Birmingham, part of the University Hospital Birmingham Trust where the Ministry of Defence had established the Royal Centre for Defence Medicine.

The inquiry found nothing to criticise in the care soldiers received but said that they were unhappy at being separated from other soldiers and lacked peer support. By 2006, senior military officers believed that this had become a threat to soldiers’ wellbeing: they wanted to be treated in a military environment “within which they can be with their mates, be looked after by named military nurses, and be treated like soldiers,” Freddie Viggers, then adjutant general, reported in …
Importance of dopamine metabolism for clinical effects and side effects of neuroleptics
Authors: H M Van Praag, J Korf
Journal: American Journal of Psychiatry (1976)

The authors studied the relation between human central dopamine (DA) metabolism and the clinical effects of neuroleptics. The neuroleptic-induced increase in central DA turnover (an indicator for the degree of DA receptor blocking) was found to be positively correlated with the therapeutic effect of neuroleptics and the development of hypokinetic-rigid symptoms. This supplies a direct argument in support of the contention that DA antagonism is related to the occurrence of clinical effects. The authors also found indications that neuroleptics of different chemical types do not significantly differ in their intrinsic ability to provoke hypokinetic-rigid symptoms, that development of these symptoms depends on the patient's individual susceptibility, and that individual susceptibility is based on relatively low DA turnover.
Collateral Damage
Authors: Michael J Brenner
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Negative, psychoticism, and disorganized dimensions in patients with familial schizophrenia or bipolar disorder: continuity and discontinuity between the major psychoses
Authors: M Maziade, M A Roy, M Martinez, D Cliche, J P Fournier, Y Garneau, L Nicole, N Montgrain, C Dion, A M Ponton
Journal: American Journal of Psychiatry (1995)

This study aimed to answer the following questions: 1) Can we reliably measure the psychopathologic dimensions of schizophrenia by using a lifetime frame and by rating acute and interepisode periods separately? 2) Can we reproduce in subjects with familial schizophrenia the characteristic three-factor structure of schizophrenic symptoms that has been found previously in general groups of schizophrenic patients? 3) Is the factor structure also present in familial bipolar disorder?Lifetime measures of psychotic symptoms were taken through a slightly modified version of the Comprehensive Assessment of Symptoms and History for 138 patients with highly familial DSM-III-R schizophrenia (N = 51), bipolar disorder (N = 44), or spectrum disorders (N = 43). Symptoms were rated separately in the acute episodes and in the stabilized interepisode intervals across the patients' lives.A satisfactory level of reliability was obtained. In this highly familial study group, the positive/negative factorial distinction was replicated, as was a three-factor model similar to that observed in prior general groups of schizophrenic patients. These factors were also present in bipolar affective disorder. The negative, psychoticism, and disorganized factor model applied more to the acute phase of illness than to the stabilized state.These findings offer an empirical basis for testing biological or genetic variables in relation to negative/positive symptom dimensions, rather than diagnoses. Observations of a shared structure for schizophrenia and bipolar disorder suggest some continuity in the causes of these disorders.
Nerve Growth Factor
Authors: William C. Mobley, Alfred C. Server, Douglas N. Ishii, Richard J. Riopelle, Eric M. Shooter
Journal: New England Journal of Medicine (1977)

Development of the Sympathetic Nervous SystemDetailed reviews of this subject have recently been published9,56 and should be consulted for additional facts and for a discussion of the development of preganglionic neurons. The general plan of sympathetic-nervous-system development in chicks and mammals is quite similar, but the earliest appearance of catecholamines in embryonic neuroblasts and the rate of maturation of the system vary with the species.56 Sympathetic development begins with migration of neural-crest cells ventrad into the mesenchyme between the neural tube and the myotome.32 These cells first take up residence in two columns dorsolateral to . . .
PD4-3-2: Observing who performance status of patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)
Authors: Ben van den Borne, Helge G. Bischoff, Frank Langer, Monika I. Leschinger, Ciara Moneley, Francisco Pimentel, Henrik Riska, Ala Szczepura, Nicholas Thatcher, Michael Thomas
Journal: Journal of Thoracic Oncology (2007)
Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML
Authors: Steven L Allen, Harry P Erba, David A. Rizzieri, Margaret O’Donnell, Bayard Powell, Ante S Lundberg, John M Bennett, Robert L Capizzi
Journal: Blood (2008)
Services for the aged in community mental health centers
Authors: R D Patterson
Journal: American Journal of Psychiatry (1976)

The author studied the services provided for the elderly at eight community mental health centers. He describes discrimination against the elderly, the reasons why relatively few elderly persons seek care, and innovations in treatment. He discovered that high-quality care depends more on staff awareness of the unique problems of the elderly than on specialized services. The author recommends a more public-health-oriented approach that would set priorities on the basis of community needs.
Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
Authors: Atul A. Deodhar, Maxime Dougados, Dominique L. Baeten, James Cheng‐Chung Wei, Piet Geusens, Aimee Readie, Hanno B. Richards, Ruvie Martin, Brian Porter
Journal: Arthritis & Rheumatology (2016)

Objective To evaluate the effect of secukinumab (interleukin‐17A inhibitor) on patient‐reported outcomes in patients with active ankylosing spondylitis (AS). Methods In this phase III study, 371 patients were randomized (1:1:1) to receive intravenous (IV) secukinumab 10 mg/kg at baseline and weeks 2 and 4 followed by subcutaneous (SC) secukinumab 150 mg every 4 weeks (IV→150 mg group), or SC secukinumab 75 mg every 4 weeks (IV→75 mg group), or placebo. Patient‐reported outcomes included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI criteria for 50% improvement (BASDAI 50), Short Form 36 (SF‐36) physical component summary (PCS) score and mental component summary (MCS) score, Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, Bath Ankylosing Spondylitis Functional Index (BASFI), EuroQol 5‐domain (EQ‐5D) questionnaire, Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), and Work Productivity and Activity Impairment–General Health questionnaire (WPAI‐GH). Results At week 16, secukinumab IV→150 mg or IV→75 mg was associated with statistically and clinically significant improvements from baseline versus placebo in the BASDAI (−2.3 for both regimens versus −0.6; P &lt; 0.0001 and P &lt; 0.001, respectively), SF‐36 PCS (5.6 for both regimens versus 1.0; P &lt; 0.0001 and P &lt; 0.001, respectively), and ASQoL (−3.6 for both regimens versus −1.0; P &lt; 0.0001 and P &lt; 0.001, respectively). Clinically significant improvements in the SF‐36 MCS, BASFI, EQ‐5D, and BASDAI 50 were observed with both secukinumab groups versus placebo at week 16; improvements were also observed in the FACIT‐F and WPAI‐GH. All improvements were sustained through week 52. Conclusion Our findings indicate that secukinumab provides significant and sustained improvements in patient‐reported disease activity and health‐related quality of life, and reduces functional impairment, fatigue, and impact of disease on work productivity in patients with active AS.
Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL).
Authors: T. D. Shanafelt, T. Call, C. S. Zent, B. LaPlant, J. F. Leis, D. Bowen, M. Roos, D. F. Jelinek, C. Erlichman, N. E. Kay
Journal: Journal of Clinical Oncology (2010)

6522 Background: Green tea has long been touted as a health promoting substance. In vitro testing and a phase I trial suggest the green tea extract epigallocatechin 3 gallate(EGCG) may have clinical efficacy for chronic lymphocytic leukemia (CLL) patients. To follow-up on these results, we performed a phase II trial of daily EGCG in patients with CLL. Methods: Previously untreated patients with asymptomatic, Rai stage 0-II CLL and a minimum absolute lymphocyte count (ALC) ≥10 x109/L were eligible for participation. Polyphenon E with a standardized dose of EGCG (2,000 mg/dose) was administered twice daily for 6 months. Response was classified using the NCI Working Group (WG) Criteria. Results: Forty-two eligible patients received EGCG 2000 mg twice daily for up to 6 months. Patients received a median of 6 cycles of treatment (range: 1-6). Accrual to the trial is complete. Thirty-one patients have completed study therapy while 11 patients have not yet completed treatment. The most common side effects included transaminitis (31% grade 1, 12% grade 2), abdominal pain (21% grade 1, 7% grade 2, 2% grade 3), and nausea (55% grade 1, 2% grade 2). Only 2/48 (4.8%) patients experienced grade 3 toxicity. One patient experienced an NCI WG partial remission. Other signs of clinical activity were observed with 13 (31%) patients experiencing a sustained ≥ 20% reduction in ALC and 19 of 29 (66%) patients with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all nodal areas during treatment. Overall 28 (67%) patients fulfilled the criteria for a biologic response (JCO 27:3808) based on attaining either a sustained ≥ 20% decline in ALC and/or a ≥ 50% reduction in the sum of the products of all nodal areas at some point during the 6 months of active treatment. Conclusions: Daily oral EGCG in the Polyphenon E preparation was well tolerated by CLL patients in this phase II trial. Declines in ALC and/or lymphadenopathy were observed in the majority of patients. EGCG containing green tea extracts may have potential as disease stabilizing agents in patients with early-stage CLL. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, Genzyme, Novartis, Polyphenon E International FDA
LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy
Authors: M. Del Prete, L. Faloppi, A. Casadei Gardini, D. Santini, N. Silvestris, M. Bianconi, R. Giampieri, A. Bittoni, K. Andrikou, M. Valgiusti, O. Brunetti, M. Scartozzi, S. Cascinu
Journal: Annals of Oncology (2015)
Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.
Authors: H. Jean Khoury, Jorge E. Cortes, Hagop Kantarjian, Michele Baccarani, Neil P. Shah, M. Brigid Bradley-Garelik, David Dejardin, Andreas Hochhaus
Journal: Blood (2010)
P-Selectin Activates Leukocyte Integrin alphaMbeta2 by Recruiting Phosphatidylinositol-3 Kinase to P-Selectin Glycoprotein Ligand-1 Cytoplasmic Domain through Adaptor Protein Naf1.
Authors: Jian-Guo Geng, Hai-Bo Wang, Ming Chen, Tao Xu, Lei Zhang, Xueliang Zhu, Edward F. Plow
Journal: Blood (2004)
P0206 : Prevention of bleeding following invasive procedures in cirrhotic patients: A single center experience
Authors: F. Invernizzi, G. Tosetti, V. La Mura, A. Aghemo, M. Primignani, A. Sanvgiovanni, M.F. Donato, A. Nicolini, M. Iavarone, M. Colombo
Journal: Journal of Hepatology (2015)
Mental health consultation in a law school clinic
Authors: R B Lacoursiere
Journal: American Journal of Psychiatry (1977)

The author describes mental health consultation with legal interns in a law school legal clinic. Unique characteristics of this setting are described, including that it is not primarily a mental health area and that the consultees are trainees. Various types of consultee-centered consultation and direct and indirect client-centered consultation are discussed, as are problems that must be avoided, e.g., an excessive psychological focus on the part of the consultant or consultee.
Trends in cancer care with the Affordable Care Act.
Authors: Tasneem Kaleem, Robert Clell Miller
Journal: Journal of Clinical Oncology (2016)

46 Background: Accountable Care Organizations (ACO), as proposed by the Affordable Care Act, will change the delivery of health care in the United States. ACO serve as a network of providers with primary care providers (PCP) set up as gate-keepers for referrals to specialists. Within the next several years, many trends will emerge and drive progress of change, requiring oncologist to take a lead role to adapt to the evolving landscape of health care. Methods: Literature search of internet-based and academic sources for oncology and the Affordable Care, with a focus on ACO formation. Results: Four main expected trends and strategies to adapt to changes were formulated. Trend 1: Changes in referral patterns towards oncologists. Referral will be based on outcome data and ACO membership. Strategy: Increase communication and education to PCP and other providers. Endorse multidisciplinary clinics, which have shown to improve guideline compliance, coordination, and communication. Trend 2: Formation of large scale oncology provider groups collaborating with PCP/ACO. Physicians will be able to provide around the clock care to patients with the goal of reducing hospital visits. Strategy: Establish oncology homes with goal of reducing inpatient and ED visits by providing telephone symptom management, daily questionnaires and opportunities for end of life discussions. Trend 3: Reimbursement reform to oncologists based on quality measures. ACO can bill fee for service basis and eligibility for bonus payments based on outcomes. Strategy:Adherence to evidence based guidelines chosen by evaluating efficacy, toxicity and cost have been proven to increase quality of patient care. Trend 4: Development to pathway driven medicine.ACO structure lends to a centralized governance committee responsible in choosing guidelines for treatment within an ACO. Strategy: Oncologists should provide a voice for the field and patients when different guidelines are chosen. Conclusions: In the context of the Affordable Care Act, oncology specialists are encouraged to participate in the new organization model to ensure best outcomes for both physicians and patients. Awareness of future trends and ways to contribute will be the first step in adapting to implementation of the Affordable Care Act.
Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease.
Authors: E Topkan, A Karaoglu
Journal: Journal of experimental & clinical cancer research (2007)

To evaluate the predictability of urine calcium (Ca+2) and deoxypyridinoline (DPD) in the assessment of response to palliative radiation therapy (RT) for metastatic bone disease. Forty-two patients with osteolytic bone metastases from breast or lung primaries were enrolled in this study. Serial urine Ca+2 and DPD measurements were performed before RT, six weeks, and twelve weeks afterwards. All eligible patients received a total of 30 Gy RT in 3 Gy daily fractions. Pre-irradiation mean urine Ca+2 and DPD levels were 16 +/- 3.7 g/micromol/dL, and 89.2 +/- 61 pmol/micromol crea. Both were significantly higher than normal range. A significant correlation between pre-irradiation Ca+2 (r = 0.6, p < 0.001), DPD (r = 0.8, p < 0.001) levels and the extent of bone metastases were detected. Thirty-six patients (Group I) were alive without disease progression outside the radiation portal. Urine Ca+2 and DPD levels demonstrated a significant and progressive decrease following RT in Group I patients (p < 0.001). Clinical and radiological evaluation revealed occurrence of new bone metastases in six patients (Group II), with concurrent significant increase in concentrations of urine DPD and Ca+2 (p = 0.006 for Ca+2 and p = 0.009 for DPD, respectively). Urine Ca+2 and DPD levels can be used for assessment of response of bone to local irradiation, and are able to predict further progression of bone metastases in cancer patients.
Metformin versus Placebo in Obese Pregnant Women without Diabetes
Authors: Fatima C Stanford, Nasreen Alfaris, Madhusmita Misra
Journal: New England Journal of Medicine (2016)

Metformin versus Placebo in Obese Pregnant Women without DiabetesTo the Editor: Syngelaki et al. (Feb.4 issue) 1 describe the efficacy of metformin in reducing gestational weight gain in women with a bodymass index (BMI; the weight in kilograms divided by the square of the height in meters) of more than 35.Although their study does not show a reduction in the neonatal birth weight, their results underscore the ability of metformin to reduce gestational weight gain in women with moderate-to-severe obesity without diabetes.One question is whether the exclusion of patients who were started on insulin after the oral glucose-tolerance test would alter the results of the study.Another question is whether a larger sample size would result in significant results for the proportion of women with miscarriages, premature births, or live births across groups.Studies have shown that metformin is safe during pregnancy, with efficacy in treating gestational diabetes mellitus and the polycystic ovary syndrome, and that the drug has no effect on the growth of several cancers. 2,3 It would be interesting if the authors of this and concurrent studies were to consider whether the use of metformin during pregnancy in women who are obese (BMI, >30) and those who are not obese (BMI, ≤30) would decrease weight retention after birth. 1,4 Postpartum weight retention contributes to obesity in all weight classes, and the use of metformin would be an attractive option to reduce this risk. 5
Evolution clinique des patients porteurs d'angiodysplasies du grêle visualisées par capsule video: suivi à 11 mois d'un groupe de 41 patients
Authors: O Favre, J Daudet, P Jacob
Journal: Endoscopy (2005)

L'exploration par capsule vidéo des saignements digestifs inexpliqués retrouve comme étiologie majoritaire les angiodysplasies du grêle. La pertinence et l'évolution clinique de cette pathologie, méconnue jusqu'ici, restant mal évaluée, nous avons étudié rétrospectivement le suivi d'une population de 41 patients consécutifs.
Persistence of asthma following avoidance of occupational allergens is associated with proTh2 myeloid dendritic cell activation
Authors: Antoine Froidure, Olivier Vandenplas, Vinciane D'Alpaos, genevieve evrard, Charles Pilette
Journal: Thorax (2015)

Background The natural history of asthma includes in some patients periods of disease remission, but the underlying mechanisms are unknown. Objectives We explored whether type 1 myeloid dendritic cell (mDC) dysfunction could be involved in the persistence of asthma, studying the controlled setting of occupational asthma (OA) after allergen avoidance. Methods We recruited 32 patients with OA to flour or latex ascertained by specific inhalation challenge and who were no longer exposed to the causal allergen. Leukapheresis was performed in each patient to isolate and characterize blood type 1 mDCs, and their functionality was studied in co-culture with allogeneic CD4+ T cells from controls. Results At follow-up, 11/32 patients (34%) were characterized by the absence of symptoms and nonspecific bronchial hyperresponsiveness to histamine and were considered to be cured. When compared to cured patients, mDCs from patients with persistent disease increased the production of IL-5 and IL-13 by CD4+ T cells, and upregulated programmed death-ligand 2 (PD-L2) upon allergen pulsing. In addition, IL-5 and IL-13 responses could be reversed by exogenous IL-12, as well as by PD-L2 blockade. Conclusions This study indicates that pro-Th2 features of mDCs correlate with disease activity in asthma after cessation of exposure to the causal allergen. The findings also highlight that the Th2 programming by DCs is flexible and partly mediated by PD-L2.
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216
Authors: D Carrie, C Caranobe, S Saivin, G Houin, M Petitou, JC Lormeau, C Van Boeckel, D Meuleman, B Boneu
Journal: Blood (1994)
O104 : Predictive model for the need for liver transplantation in symptomatic polycystic liver disease
Authors: F. Temmerman, M. Oliverius, J. Lerut, J.P. Drenth, H. Metselaar, W. Coudyzer, R. Vanslembrouck, J. van Pelt, B. Bammens, J. Pirenne, F. Nevens
Journal: Journal of Hepatology (2015)
Use of the Japanese Live Attenuated High-Titer Varicella Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
Authors: Takahiro Aoki, Katsuyoshi Koh, Yutaka Kawano, Chigusa Oyama, Yuhachi Ikeda, Yasuo Kubota, Kiyotaka Isobe, Ryo Oyama, Makiko Mori, Yuki Awakawa, Motohiro Kato, Ryoji Hanada
Journal: Blood (2014)